Baseline | Discharge | 3 months | ANOVA | |
mPAP mmHg | 57±11 | 54±11 | 49±11* | 0.01 |
PAWP mmHg | 9.7±3 | 8.8±3.8 | 7.7±3.9* | 0.052 |
RAP mmHg | 13±5.7 | 12±4.9 | 7.5±4.5*,# | 0.0001 |
CI L·min−1·m−2 | 2.1±0.6 | 2.5±0.8* | 2.9±0.8* | <0.0001 |
PVR mmHg·L−1·min−1 | 13±4.5 | 12±5.4 | 8.3±3.6*,# | 0.0002 |
Ees mmHg·mL−1 | 3.2±1.9 | 1.7±0.8* | 1.9±0.9* | <0.0001 |
Ea mmHg·mL−1 | 1.6±0.9 | 1±0.5* | 1±0.5* | 0.0002 |
Ees/Ea | 2.0±0.7 | 1.7±0.7 | 2.1±0.7 | 0.09 |
V0 mL | 141±43 | 104±54* | 102±54* | 0.02 |
RVEF % | 21±8.3 | 30±8.7* | 32±10* | <0.0001 |
SV/ESV | 0.3±0.1 | 0.5±0.2* | 0.5±0.2* | <0.0001 |
Beta mL−1 | 0.08±0.04 | 0.05±0.02* | 0.05±0.02* | <0.0001 |
Eed mmHg·mL−1 | 1.7±1.1 | 1.0±0.5* | 0.7±0.5* | <0.0001 |
6-min walk distance m | 269±109 | 327±155* | ||
BNP pg·mL−1 | 623±449 | 280±235* | 187±183* | <0.0001 |
Data are presented as mean±SD. The ANOVA column shows the significance of the F-ratios of the analysis of variance *: p<0.05 versus baseline; #: p<0.05 high versus low dose of treprostinil. mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; RAP: right atrial pressure; CI: cardiac index; PVR: pulmonary vascular resistance; Ees: end-systolic elastance; Ea: arterial elastance; V0: pressure volume intercept; RVEF: right ventricle ejection fraction; SV: stroke volume; ESV: end-systolic volume; Eed: end-diastolic elastance; BNP: brain natriuretic peptide.